Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Ubiquitin-conjugating enzyme E2 L5 (UBE2L5) is a member of the E2 family of enzymes, which play a central role in the ubiquitination pathway. UBE2L5 catalyzes the transfer of ubiquitin from E1 (activating enzymes) to substrate proteins, usually in concert with an E3 (ligase), marking them for proteasomal degradation or altering their cellular function. This enzyme is predicted to participate in K11-linked ubiquitination and is primarily active in the nucleus. An important paralog is UBE2L3. UBE2L5 is part of the overall ubiquitin-proteasome system that regulates protein turnover and quality control in cells. There are no well-documented direct disease roles, interacting drugs, or safety concerns specifically associated with UBE2L5 as of current knowledge.
Conjugation of ubiquitin to substrate proteins (via interaction with E1 and E3 enzymes)
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Ubiquitin-conjugating enzyme E2 L5 (UBE2L5).